GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14.
The agreement includes a $1.2 billion upfront payment along with an additional $800 million tied to future development and regulatory agreements.
As part of the deal, GSK will acquire Boston Pharmaceuticals’ subsidiary BP Asset IX to gain full rights to the drug. Efimosfermin, aimed at treating steatotic liver disease, is in late-stage trials and could reach the market by 2029.
